DE69518319D1 - Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung - Google Patents

Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung

Info

Publication number
DE69518319D1
DE69518319D1 DE69518319T DE69518319T DE69518319D1 DE 69518319 D1 DE69518319 D1 DE 69518319D1 DE 69518319 T DE69518319 T DE 69518319T DE 69518319 T DE69518319 T DE 69518319T DE 69518319 D1 DE69518319 D1 DE 69518319D1
Authority
DE
Germany
Prior art keywords
peptides
proteins
stabilization
active substances
radiopharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69518319T
Other languages
English (en)
Other versions
DE69518319T2 (de
Inventor
Kathleen M Miller
La Fourniere Laurence De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of DE69518319D1 publication Critical patent/DE69518319D1/de
Application granted granted Critical
Publication of DE69518319T2 publication Critical patent/DE69518319T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69518319T 1994-03-16 1995-03-16 Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung Expired - Fee Related DE69518319T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21434794A 1994-03-16 1994-03-16
PCT/US1995/003180 WO1995025119A1 (en) 1994-03-16 1995-03-16 Stabilization of peptides and proteins for radiopharmaceutical use

Publications (2)

Publication Number Publication Date
DE69518319D1 true DE69518319D1 (de) 2000-09-14
DE69518319T2 DE69518319T2 (de) 2000-12-14

Family

ID=22798713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518319T Expired - Fee Related DE69518319T2 (de) 1994-03-16 1995-03-16 Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung

Country Status (8)

Country Link
US (1) US6174513B1 (de)
EP (1) EP0763056B1 (de)
JP (1) JP3812680B2 (de)
AT (1) ATE195322T1 (de)
CA (1) CA2185653C (de)
DE (1) DE69518319T2 (de)
HU (1) HUT76623A (de)
WO (1) WO1995025119A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187099A1 (en) * 2001-05-16 2002-12-12 Rajesh Manchanda Stabilization of radionuclide-containing compositions
ITBA20020032A1 (it) * 2002-09-24 2004-03-25 Bio D Soc Metodo per stabilizzare le proteine per la conservazione ad alte temperature.
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
WO2016021678A1 (ja) * 2014-08-08 2016-02-11 日油株式会社 蛋白質安定化剤及び蛋白質安定化方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012926B1 (de) * 1978-12-19 1984-03-07 Byk Gulden Lomberg Chemische Fabrik GmbH Röntgenkontrastmittellösungen
US4853330A (en) * 1983-04-07 1989-08-01 Genentech, Inc. Human tissue plasminogen activator
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
CA2066779A1 (en) * 1989-09-22 1991-03-23 Jean-Luc Vanderheyden Stable therapeutic radionuclide compositions and methods for preparation thereof
DE4040817A1 (de) * 1989-12-27 1991-07-04 Boehringer Ingelheim Int Verwendung eines antikoagulant als diagnostikum
US5080883A (en) * 1990-05-11 1992-01-14 Mallinckrodt, Inc. 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging
US5328898A (en) * 1990-06-22 1994-07-12 Duke University Factor XIIIA fibrin binding fragments
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents

Also Published As

Publication number Publication date
HU9602554D0 (en) 1996-11-28
JP3812680B2 (ja) 2006-08-23
WO1995025119A1 (en) 1995-09-21
CA2185653C (en) 2009-01-13
EP0763056B1 (de) 2000-08-09
CA2185653A1 (en) 1995-09-21
EP0763056A4 (de) 1997-07-30
JPH09510454A (ja) 1997-10-21
US6174513B1 (en) 2001-01-16
EP0763056A1 (de) 1997-03-19
ATE195322T1 (de) 2000-08-15
HUT76623A (en) 1997-10-28
DE69518319T2 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
DE69231469D1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE69034018T2 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
IT1256248B (it) Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
DK382786A (da) Overfladeaktivt rekombinant-alveolarprotein
ATE123070T1 (de) Monoklonale antikörper gegen den rezeptor des epidermis-wachstumsfaktors und diese enthaltende therapeutische zubereitungen.
DE68926248D1 (de) p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
ID27862A (id) Metode-metode untuk pengontrolan bau badan sekitar pada tubuh yang menggunakan komposisi-komposisi yang terdiri dari senyawa non-komplek siklodekstrins dan pewangi
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
BR9403783A (pt) Uso de uma composição cosmética
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
ATA903489A (de) Protoporphyrinogeninhibitoren und deren verwendung in zusammensetzungen zur erkennung und behandlung von tumoren
DE69840932D1 (de) Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen
DE69512929D1 (de) Salze von aminoalkoholen und diese enthaltende pharmazeutische zusammensetzungen
HUP9900506A2 (hu) Protrombinszármazékok
DE69518319T2 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DE69831257D1 (de) Histogranin peptide und deren analgetische verwendung
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ATE132758T1 (de) Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
BR9712793A (pt) Fatores homólogos (fhfs) ao fator do desenvolvimento de fibroblasto e métodos de uso
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee